Morgan Stanley lowered the firm’s price target on Bayer (BAYRY) to EUR 53 from EUR 55 and keeps an Overweight rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BAYRY:
- Bayer Targets Earlier Prostate Cancer Use for Darolutamide With New China Phase 2 Trial
- Bayer Earnings Call: Solid Execution, Heavy Legal Overhang
- Bayer ‘pleased’ with court’s preliminary approval of Roundup class settlement
- Midday Fly By: Stocks climb as oil prices pull back
- Court preliminary approves Bayer’s Roundup settlement, Bloomberg says